Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma

Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma presents a 5-year overall survival rate of 11%, placing an imperative need for the discovery and application of innovative treatments. Radiofrequency ablation represents a promising therapy for PDA, as studies show it induces coagulative necrosis and a host adaptive...

Full description

Bibliographic Details
Main Authors: Erika Y. Faraoni, Lincoln N. Strickland, Baylee J. O’Brien, Joseph F. Barraza, Nirav C. Thosani, Curtis J. Wray, Tingting W. Mills, Jennifer M. Bailey-Lundberg
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
pancreatic cancer
CD73
adenosine
AB680
inosine
radiofrequency ablation
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.995027/full

Similar Items

Similar Items